- Home
- Products
- Customized ADCs
- Pseudomonas Aeruginosa Serotype IATS O11
- Anti-Pseudomonas aeruginosa serotype IATS O11 (Panobacumab)-MC-Vc-PAB-MMAE ADC
Anti-Pseudomonas aeruginosa serotype IATS O11 (Panobacumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2033)
This ADC product is comprised of an anti-Pseudomonas aeruginosa serotype IATS O11 monoclonal antibody conjugated via a MC-Vc linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- Pseudomonas aeruginosa serotype IATS O11
- Alternative Names
- Pseudomonas aeruginosa serotype IATS O11
- Overview
- P. aeruginosa is Gram-negative, aerobic, rod-shaped bacteria with unipolar motility. An opportunistic human pathogen, P. aeruginosa is also an opportunistic pathogen of plants. P. aeruginosa bacteria are clinically important because they are resistant to most antibiotics and they are capable of surviving in conditions that few other organisms can tolerate. Pseudomonas is often encountered in hospital and clinical work because it is a major cause of hospital acquired (nosocomal) infections. Its main targets are immunocompromised individuals, burn victims, and individuals on respirators or with indwelling catheters. Additionally, these pathogens colonize the lungs of cystic fibrosis patients. P. aeruginosa is often identified by its pearlescent appearance and grape-like odor in vitro. Definitive clinical identification of P. aeruginosa includes identifying the production of both pyocyanin and fluorescein as well as its ability to grow at 42°C. P. aeruginosa is capable of growth in diesel and jet fuel, where it is known as hydrocarbon utilizing microorganisms (or "HUM bugs"), causing microbial corrosion. It creates dark gellish mats sometimes improperly called "algae".
- Overview
- Human Anti-Pseudomonas aeruginosa serotype IATS O11 IgM-kappa antibody, Panobacumab
- Generic name
- Panobacumab
- Host animal
- Human
- Name
- MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- MMAE
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-EGFR (Futuximab)-SMCC-DM1 ADC (CAT#: ADC-W-1046)
- Anti-ITIH4-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-228)
- Anti-Rabies Virus Glycoprotein (Foravirumab)-SMCC-DM1 ADC (CAT#: ADC-W-1964)
- Anti-thrombin inhibitor (BIBR_953) (Idarucizumab)-SMCC-DM1 ADC (CAT#: ADC-W-2408)
- Anti-HBV (Exbivirumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2076)
- Anti-CD70-MCC-DM1 ADC (CAT#: ADC-W-487)
- Anti-EGFR (Imgatuzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1067)
- Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2568)
- Anti-ERBB2(Trastuzumab)-VC-Duostatin-3 ADC (CAT#: ADC-W-530)
- Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1117)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2033. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2035 | Anti-Pseudomonas aeruginosa serotype IATS O11 (Panobacumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2034 | Anti-Pseudomonas aeruginosa serotype IATS O11 (Panobacumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2032 | Anti-Pseudomonas aeruginosa serotype IATS O11 (Panobacumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-2030 | Anti-Pseudomonas aeruginosa serotype IATS O11 (Panobacumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2031 | Anti-Pseudomonas aeruginosa serotype IATS O11 (Panobacumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-2581 | Anti-CEACAM5-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2618 | Anti-MS4A1-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2607 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2587 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2601 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-2592 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2551 | Anti-CD74-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2613 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2568 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-2545 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.